March 11, 2024 — VahatiCor, Inc., a medical technology company focused on helping patients with persistent ischemic heart disease, announced the A-FLUX Reducer System, a treatment for patients with angina and chest pain. Presented the treatment of the first patient.

Angina is often caused by decreased blood flow to the heart. This condition can occur in people with or without significant blockages in large coronary arteries. It often involves decreased blood flow in very small blood vessels that branch from the coronary arteries, a condition known as coronary microvascular insufficiency or microvascular angina.

According to published documents, the A-FLUX Reducer implant is placed in the coronary sinus, the heart’s largest vein, to provide more blood flow to ischemic areas of the heart, improving symptoms and quality of life for patients. It is said to be designed to. Written by Bahati Kol.

The A-FLUX Reducer System is an investigational medical device and may not be commercially distributed.

The first patient received an A-FLUX Reducer implant through Health Canada’s Special Access Program (SAP). A prospective, multicenter clinical study of the device is scheduled to begin enrollment this year.

“We have a number of interventional or surgical revascularization options available to patients with advanced coronary artery disease. However, a significant proportion still suffer from angina.” A-FLUX Reducer could help fill that therapeutic gap. We are honored to have performed the first human implant and the patient is doing well,” said the Quebec Heart and Lung Institute, which co-treated the first patient. said Dr. Jean-Michel Paradis, an expert in coronary and structural interventional cardiology at . .

“The A-FLUX Reducer System is a promising product with the potential to provide a predictable, low-risk treatment for the growing number of patients with angina symptoms that do not respond well to medications or lifestyle changes. This is a significant intervention,” added Dr. Can Manh Nguyen. , an interventional cardiologist who co-treated the first patient with Dr. Paradis.

According to the American Heart Association (AHA), more than 20 million people in North America and Europe have symptoms of angina, and 4 million people undergo invasive diagnostic angiography each year.^1-4

“While many interventions are available to treat blockages in large coronary arteries, there are few options for the even larger group of patients with microvascular angina,” said Howard Edelman, CEO of VahatiCor. states. “We are encouraged by the positive early clinical experience with A-FLUX and are moving quickly to large-scale studies that will help bring this device to more patients,” said Edelman. added.

Santa Clara, California-based VahatiCor, Inc. is a member of the T45 Labs portfolio. T45 Labs is a medical technology innovation company located in Santa Clara, California’s Silicon Valley. VahatiCor further said it is developing medical devices that address unmet clinical needs to raise the standard of care for people with angina and other heart conditions.

For more information, please visit www.vahaticor.com.

reference

^1. Mozaffarian D et al. Heart disease and stroke statistics – 2016 update: American Heart Association report. Circulation. 2016; 133:e38–e360

^2. According to the European Society of Cardiology, diseases of the smallest blood vessels of the heart are an important global health problem. May 27, 2021.

^3. Cook S, Walker A, Hügli O, Togni M, Meier B. Percutaneous coronary interventions in Europe: prevalence, numerical estimates, and projections based on data up to 2004. Clin Res Cardiol. 2007;96(6):375 382.

^Four. Patel MR, Peterson ED, Dai D, et al. Low diagnostic yield of selective coronary angiography. N Eng J Med 2010;362(10):886 895.